4-Sep-2026
Globe Newswire (Tue, 23-Jun 4:03 PM ET)
PRNewswire (Tue, 23-Jun 1:00 PM ET)
Business Wire (Tue, 23-Jun 12:33 PM ET)
PRNewswire (Tue, 23-Jun 10:00 AM ET)
Business Wire (Tue, 23-Jun 8:49 AM ET)
Globe Newswire (Mon, 22-Jun 5:16 PM ET)
Business Wire (Mon, 22-Jun 12:46 PM ET)
Globe Newswire (Mon, 22-Jun 10:17 AM ET)
Globe Newswire (Sun, 21-Jun 10:37 PM ET)
Globe Newswire (Sat, 20-Jun 8:09 PM ET)
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
Regencell Bioscience Holdings Limited - trades on the NASDAQ stock market under the symbol RGC.
As of September 4, 2026, RGC stock price climbed to $6.89 with 651,778 million shares trading.
RGC has a beta of 2.42, meaning it tends to be more sensitive to market movements. RGC has a correlation of 0.04 to the broad based SPY ETF.
RGC has a market cap of $3.41 billion. This is considered a Mid Cap stock.
In the last 3 years, RGC traded as high as $83.60 and as low as $.08.
The top ETF exchange traded funds that RGC belongs to (by Net Assets): ONEQ, GXC, EEMO.
RGC has underperformed the market in the last year with a return of -46.3%, while the SPY ETF gained +19.8%. In the last 3 month period, RGC fell short of the market, returning -68.9%, while SPY returned +2.0%. However, in the most recent 2 weeks RGC has outperformed the stock market by returning +30.0%, while SPY returned +0.6%.
RGC support price is $6.11 and resistance is $6.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGC shares will trade within this expected range on the day.
